EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY 4.0

Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial

Caroline Holzmann, Johannes Karg, Matthias Reiger, Rajiv Kharbal, Paola Romano, Sabrina Scheiwein, Claudia Khalfi, Anna Muzalyova, Jens O Brunner, Gertrud Hammel iD, Athanasios Damialis iD, Claudia Traidl-Hoffmann and 2 more

Allergy · 2025

DOI: 10.1111/all.16558 ↗

At a glance

Randomisierte kontrollierte Studie in Allergy, 2025. Written by Caroline Holzmann and 13 co-authors. Institution: Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University Hospital Augsburg, Augsburg, Germany. Major MEDLINE topics: Rhinitis, Allergic, Seasonal, Pollen, Mobile Applications, Poaceae. Cited 8 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY 4.0). Funded by: Bayerisches Landesamt für Gesunheit und Lebensmittelsicherheit (LGL), German Ministry of Research and Education (BMBF).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Symptom monitoring can improve adherence to daily medication. However, controlled clinical trials on multi‐modular allergy apps and their various functions have been difficult to implement. The objective of this study was to assess the clinical benefit of an allergy app with varying numbers of functions in reducing symptoms and improving quality of (QoL) life in grass pollen allergic individuals. The secondary objective was to develop a symptom forecast based on patient‐derived and environmental data.

Methods

We performed a stratified, controlled intervention study (May–August 2023) with grass pollen allergic participants ( N = 167) in Augsburg, Germany. Participants were divided into three groups, each receiving the same allergy app, but with increasing numbers of functions. Primary endpoint: rhinitis‐related QoL; Secondary endpoints: symptom scores, relevant behavior, self‐reported usefulness of the app, symptom forecast.

Results

Rhinitis‐related QoL was increased after the intervention, with no statistical inter‐group differences. However, participants with access to the full app version, including a pollen forecast, took more medication and reported lower symptoms and social activity impairment than participants with access to a reduced‐function app. Using an XGBoost multiclass classification model, we achieved promising results for predicting nasal (accuracy: 0.79; F1‐score: 0.78) and ocular (accuracy: 0.82; F1‐score: 0.76) symptom levels and derived feature importance using SHAP as a guidance for future approaches.

Conclusion

Our allergy app with its high‐performance pollen forecast, symptom diary, and general allergy‐related information provides a clinical benefit for allergy sufferers. Reliable symptom forecasts may be created given high‐quality and high‐resolution data.

Subjects

MeSH terms (MEDLINE)

Rhinitis, Allergic, SeasonalPollenMobile ApplicationsPoaceaeHumansQuality of LifeMaleFemaleAdultMiddle AgedAllergensYoung Adult

Author keywords

allergic rhinitisallergy appclinical studypollen forecastsymptom forecast

Substances

Allergens

Authors and institutions

  • Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University Hospital Augsburg, Augsburg, Germany.
  • Institute of Environmental Medicine, Helmholtz Munich-German Research Center for Environmental Health, Augsburg, Germany.
  • Outpatient Clinic for Environmental Medicine, University Hospital Augsburg, Augsburg, Germany.
  • Institute for Digital Medicine, University Hospital Augsburg, Augsburg, Germany.
  • Department of Technology, Management, and Economics, Technical University of Denmark, Copenhagen, Denmark.
  • Next Generation Technology, Region Zealand, Denmark.

ORCID profiles: Gertrud Hammel, Athanasios Damialis

Funding

  • Bayerisches Landesamt für Gesunheit und Lebensmittelsicherheit (LGL)
  • German Ministry of Research and Education (BMBF)

Cite

APA

Holzmann, C., Karg, J., Reiger, M., Kharbal, R., Romano, P., Scheiwein, S., Khalfi, C., Muzalyova, A., Brunner, J. O., Hammel, G., Damialis, A., Traidl-Hoffmann, C., Plaza, M. P., & Gilles, S. (2025). Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial. Allergy. https://doi.org/10.1111/all.16558

Vancouver

Holzmann C, Karg J, Reiger M, Kharbal R, Romano P, Scheiwein S, et al. Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial. Allergy. 2025. doi:10.1111/all.16558

BibTeX
@article{Holzmann2025,
  author = {Holzmann, Caroline and Karg, Johannes and Reiger, Matthias and Kharbal, Rajiv and Romano, Paola and Scheiwein, Sabrina and Khalfi, Claudia and Muzalyova, Anna and Brunner, Jens O and Hammel, Gertrud and Damialis, Athanasios and Traidl-Hoffmann, Claudia and Plaza, María P and Gilles, Stefanie},
  title = {Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16558}
}
Start for free →